The role of PBMs, patents, and public health in drug pricing

Prescription drug costs are remarkably higher in the United States than in other countries, so it’s no surprise that more than half of U.S. adults say they are worried about being able to afford their medications. These high costs have led many people to skip doses, take less than the prescribed amount, delay filling prescriptions, and even go without treatment altogether.

But why are prices so high in the first place? And why is it so hard to rein them in?

In this video series, we take you behind the pharmacy counter to explore the factors involved in pricing prescription drugs. We look at how a complex relationship between drugmakers, insurers, and pharmacy benefit managers contributes to increasing drug costs. We also do a deep dive on drug patents — how they’re obtained, how they’re used, and how they can mean the difference between a drug costing hundreds of dollars or the equivalent of a cup of coffee.

Part 1 presents the 30,000-foot view of this landscape, in which the rules for competition and innovation can help incentivize drugmakers to produce crucial medicines, but these incentives can also harm patient access and public health. Conversely, fewer incentives can mean the development of fewer treatments, which can also harm people in need. 

This all presents a central question that we’ll return to throughout the series: How do we balance the demands of the pharmaceutical industry with the needs of patients?

More from STAT:

Become a subscriber: https://www.statnews.com/stat-plus/
Watch Full Episodes:    / @statnews  
Newsletters: https://www.statnews.com/signup/
STAT events: https://www.statnews.com/stat-events/
Facebook:   / statnews  
Twitter:   / statnews  
Instagram:   / statnews  
Flipboard: rb.gy/3xnsxr
STAT Reports: https://rb.gy/rexfwj
STAT eBooks: https://rb.gy/eme3h5

ABOUT STAT:
Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.